Aspirin for primary prevention of cardiovascular disease in patients with diabetes: a meta-analysis

Highlights • CVD is the leading cause of morbidity and mortality for patients with diabetes. • The benefit of aspirin used for CVD primary prevention is controversial. • Meta-analyses report aspirin does not prevent CVD endpoints nor increase bleeding. • Several atherosclerotic endpoints were not in...

Full description

Saved in:
Bibliographic Details
Published in:Diabetes research and clinical practice 2016-10, Vol.120, p.31-39
Main Authors: Kokoska, Lianne A, Wilhelm, Sheila M, Garwood, Candice L, Berlie, Helen D
Format: Article
Language:English
Subjects:
Anti-Inflammatory Agents, Non-Steroidal - therapeutic use
Aspirin
Aspirin - therapeutic use
Atherosclerosis
Cardiovascular disease
Cardiovascular Diseases - etiology
Cardiovascular Diseases - prevention & control
Diabetes Complications - etiology
Diabetes Complications - prevention & control
Diabetes mellitus
Diabetes Mellitus - physiopathology
Endocrinology & Metabolism
Humans
Primary Prevention
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Highlights • CVD is the leading cause of morbidity and mortality for patients with diabetes. • The benefit of aspirin used for CVD primary prevention is controversial. • Meta-analyses report aspirin does not prevent CVD endpoints nor increase bleeding. • Several atherosclerotic endpoints were not included in previous meta-analyses. • This meta-analysis found no difference of atherosclerotic events with aspirin vs. placebo.
ISSN:0168-8227
1872-8227
DOI:10.1016/j.diabres.2016.07.012